Cancer News and Research

Latest Cancer News and Research

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

11 Oct 2010

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.

11 Oct 2010

Identifying subsets of patients who will respond to subsequent lines of chemotherapy

In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.

11 Oct 2010

Phase 3 study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.

11 Oct 2010

Fertility concerns of cancer survivors inadequately addressed, study finds

Many cancer survivors experience changes in sexual function that leave them feeling guilty and a longing for intimacy, Australian researchers told at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. The researchers say that these sexuality and fertility concerns are often not adequately addressed by doctors.

11 Oct 2010

Sexual issues a major concern for cancer patients taking new targeted drugs

New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient’s sex life, researchers have found. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, French researchers reported on one of the few studies to investigate the impact of cancer therapy on the sexual functioning of patients.

11 Oct 2010

Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds

Researchers in Canada and France have raised concerns about substantial inconsistencies in a basic aspect of the way Phase-I and Phase-II cancer clinical trials are designed.

11 Oct 2010

New phase 2 study shows first-line promise of lung cancer drug PF-299

A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Patients with metastatic castration-resistant prostate cancer who have progressed after chemotherapy live significantly longer if treated with the drug abiraterone acetate compared to placebo, the results of a large Phase-III clinical trial confirm.

11 Oct 2010

$Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer$

Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer

An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show.

11 Oct 2010

Final results from landmark trial confirm survival benefits of EGFR mutations in lung cancer

Mature results from a landmark Phase-III trial have confirmed that patients with EGFR mutation-positive advanced non-small cell lung cancer have better overall survival when treated with gefitinib or chemotherapy than patients whose tumors do not carry such mutations.

11 Oct 2010

Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer

Early results from a large Phase-III trial suggest that adding bevacizumab to chemotherapy as a treatment for newly diagnosed ovarian cancer reduces the risk of disease progression during the first year of treatment. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Tim Perren from Leeds Teaching Hospitals NHS Trust, UK, reported findings from the international ICON7 trial, which included 1528 women with high-risk early or advanced stage epithelial ovarian cancer, primary peritoneal cancer or Fallopian tube cancer.

11 Oct 2010

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

European researchers have proven for the first time that targeting the epidermal growth factor receptor can provide substantial clinical benefit for women with hard-to-treat triple-negative breast cancer.

11 Oct 2010

Embryonic stem cells used in first trial for spinal cord injury

The first ever patient to receive treatment in a U.S. government approved study involving human embryonic stem cells has been injected with millions of the potentially life saving cells. He is presently being treated at the Shepherd Center in Atlanta. He was partially paralyzed following a spinal cord injury. The center specializes in treating these types of injuries.

11 Oct 2010

ZeroNines launches ZenVault Medical Personal Health Record portal

ZeroNines® Technology, Inc. announced the launch of ZenVault™ Medical, a Personal Health Record portal (PHR) that gives consumers instant, secure, private access to their medical records online. ZenVault Medical was specifically designed to address the public's concerns over data security, privacy, convenience, and expense associated with the national push to convert from traditional paper to digital medical records.

11 Oct 2010

Atomic Tattoos launches 'Tats for Tatas' breast cancer awareness fundraising campaign

Atomic Tattoos has announced the launch of their "Tats for Tatas" fundraising campaign that will take place throughout October, benefiting the Florida Breast Cancer Foundation in Florida and Southeast Regional Breast Cancer Fund in Wisconsin. In the company's concerted efforts to raise awareness and funds for Breast Cancer Awareness, Atomic Tattoos is offering several specials throughout the month if customers donate $5 to breast cancer awareness.

11 Oct 2010

Incentivized structured weight loss program with free prepared meals effectively promotes weight loss

In another article being released early online, Cheryl L. Rock, Ph.D., R.D., from Moores UCSD Cancer Center, La Jolla, Calif., and colleagues, conducted a randomized controlled trial of weight loss and weight maintenance in 442 overweight or obese women (BMI, 25 - 40), ages 18 to 69, over a two year period with follow-up between November 2007 and April 2010.

11 Oct 2010

DATATRAK signs agreement for three new Phase III oncology studies

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of an Enterprise Agreement for three new Phase III oncology studies with an existing client. These multi-center studies will be deployed utilizing the unified DATATRAK eClinical™ platform.

11 Oct 2010

Access highlights clinical benefits of MuGard at ESMO conference

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy.

11 Oct 2010

Cancer News and Research

Latest Cancer News and Research

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

Identifying subsets of patients who will respond to subsequent lines of chemotherapy

Phase 3 study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

Fertility concerns of cancer survivors inadequately addressed, study finds

Sexual issues a major concern for cancer patients taking new targeted drugs

Early cancer drug trials flawed by inconsistencies in prohibited drug lists, study finds

New phase 2 study shows first-line promise of lung cancer drug PF-299

Abiraterone acetate improves survival in metastatic castration-resistant prostate cancer

Pazopanib shows promise in phase-2 trial for relapsed/refractory urothelial cancer

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

Final results from landmark trial confirm survival benefits of EGFR mutations in lung cancer

Research suggests bevacizumab delays progression in newly diagnosed ovarian cancer

Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

Embryonic stem cells used in first trial for spinal cord injury

ZeroNines launches ZenVault Medical Personal Health Record portal

Atomic Tattoos launches 'Tats for Tatas' breast cancer awareness fundraising campaign

Incentivized structured weight loss program with free prepared meals effectively promotes weight loss

DATATRAK signs agreement for three new Phase III oncology studies

Access highlights clinical benefits of MuGard at ESMO conference

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in